Twitter Facebook
Contact the Author |

13 Jul

The Lancet Oncolgy. Vol.16, No.4, e190-e194. April 2015

Personel View

Authors: Prof. David Ashley PhD, Prof. David Thomas Ph.D, Prof. Lisa Gore MD, Prof. Rob Carter Ph.D, Prof. John R Zalcberg Ph.D, Prof.Renee Otmar Ph.D, Prof Julian Savulescu Ph.D


Rare cancers collectively contribute a disproportionate fraction of the total burden of cancer. The oncology community is increasingly facing small numbers of patients with each cancer subtype, requiring cooperation and collaboration to complete multicentre trials that advance knowledge and patient care. At the same time, new insights into the biology of rare cancers have led to an explosion in knowledge and development of targeted agents. These insights and techniques are set to revolutionise the care of patients with cancer. However, drug development strategies and the availability of new agents for rare cancers are at risk of stalling owing to the ever-increasing complexity and costs of clinical trials. Finding solutions to these problems is imperative to the future of cancer care. We propose that a greater degree of risk sharing is needed than is currently accepted to enable the use of new methods with confidence, and to keep pace with scientific advancement.


Leave a Reply

Your email address will not be published.